Oral Complications from Oropharyngeal Cancer Therapy
Cancers,
Год журнала:
2023,
Номер
15(18), С. 4548 - 4548
Опубликована: Сен. 14, 2023
Post-oropharyngeal
cancer
treatment
complications
include
a
multitude
of
oral
side
effects
that
impact
overall
survival
and
quality
life.
These
acute
chronic
conditions
affecting
the
cavity
head
neck,
such
as
mucositis,
infection,
xerostomia,
dysgeusia,
radiation
caries,
osteonecrosis,
trismus.
This
review
will
summarize
most
common
from
oropharyngeal
therapy.
The
authors
would
like
to
point
out
literature
cited
frequently
combines
neck
results.
If
recommendations
are
made
strictly
related
cancers,
this
be
highlighted.
Язык: Английский
Avasopasem for the treatment of radiotherapy-induced severe oral mucositis
Expert Opinion on Investigational Drugs,
Год журнала:
2023,
Номер
32(6), С. 463 - 470
Опубликована: Июнь 3, 2023
ABSTRACTIntroduction
Oral
mucositis
(OM)
remains
a
significant,
highly
symptomatic,
disruptive
side
effect
of
radiation
and
concomitant
chemoradiation
therapy
used
for
the
treatment
squamous
cell
cancers
head
neck.
Despite
its
clinical
economic
burden,
implementation
an
effective
intervention
has
been
elusive.Areas
covered
Increased
understanding
complexity
biological
basis
pathogenesis
yielded
potential
druggable
targets
such
as
mitigation
superoxide
formation
oxidative
stress.
Avasopasem
manganese
is
selective
dismutase
mimetic
being
developed
by
Galera
Therapeutics,
which
recently
submitted
New
Drug
Application
(NDA)
to
FDA
severe
OM
indication.
This
review
describes
preclinical
studies
led
to,
supported
NDA,
assesses
utility
avasopasem
clinically.Expert
opinion
appears
effectively
mitigate
associated
with
in
neck
cancers,
well
cisplatin-associated
renal
toxicity
absence
impairing
tumor
response.KEYWORDS:
mucositisradiationchemoradiationhead
canceravasopasem
manganeseclinical
development
Article
highlights
common,
treatment-limiting
standard
regimens
neck.Oxidative
stress
critical
component
initiation
events
precipitate
development.Avasopasem
manganese,
mimetic,
supplement
naturally
occurring
antioxidant
mechanism
favorably
protect
normal
oral
mucosa
while
not
interfering
radiosensitivity.Pre-clinical
data
have
consistently
indicated
that
safe
mitigating
course
incidence
regimens.The
requirement
intravenous
administration
proximity
could
require
infrastructure
changes
high
volume
practices
and/or
coordination
between
radiotherapy
sites
infusion
centers.Avasopasem
be
positioned
breakthrough
otherwise
unmanageable
complication
therapy.Declaration
interestDr
Sonis
employee
Biomodels,
LLC
Primary
Endpoint
Solutions,
LLC.
Both
companies
assist
industry,
government,
academics
study
enable
drugs,
biologicals,
devices
treat
patients
variety
indications
including
cancer
effects
toxicities
treatment.
done
contract
work
Galera.
Dr
does
equity
any
either
organization
works.The
authors
no
other
relevant
affiliations
or
financial
involvement
entity
interest
conflict
subject
matter
materials
discussed
manuscript
apart
from
those
disclosed.Reviewer
disclosuresPeer
reviewers
on
this
relationships
disclose.AcknowledgmentsWe
thank
Robert
Beardsley
providing
historical
background
manganese.Additional
informationFundingThis
paper
was
funded.
Язык: Английский
Taste dysfunction symptoms experience in head and neck cancer patients undergoing proton and heavy ion therapy: a qualitative study
Supportive Care in Cancer,
Год журнала:
2024,
Номер
33(1)
Опубликована: Дек. 11, 2024
Язык: Английский
Toxicity with proton therapy for oral and/or oropharyngeal cancers
Journal of Oral Pathology and Medicine,
Год журнала:
2023,
Номер
52(5), С. 456 - 457
Опубликована: Март 24, 2023
The
peer
review
history
for
this
article
is
available
at
https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/jop.13431.
letter
to
the
editor
does
not
contain
original
data
from
Erkan
Topkan,
Busra
Yilmaz,
Efsun
Somay,
and
Ugur
Selek.
Therefore,
availability
statement
applicable.
Язык: Английский